Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
This study has been completed.
Study NCT00566735 Information provided by Massachusetts General Hospital
First Received: December 3, 2007 Last Updated: August 18, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Major Depression
Bipolar Depression
Additional conditions recognized in this trial
Bipolar Disorder
Depression
Depressive Disorder
Depressive Disorder, Major
Psychotic Disorders
More general conditions related to this trial
Affective Disorders, Psychotic
Behavioral Symptoms
Mental Disorders
Mood Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Razadyne
Placebo
Additional drug interventions recognized in this trial
Galantamine
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Cholinergic Agents
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Massachusetts General Hospital
Ortho-McNeil Janssen Scientific Affairs, LLC
Back to top of Main Content
